A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects With Diffuse Diabetic Macular Edema.

Trial Profile

A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects With Diffuse Diabetic Macular Edema.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2012

At a glance

  • Drugs ICO-007 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors iCo Therapeutics
  • Most Recent Events

    • 21 Mar 2012 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 18 May 2010 Status changed from active, no longer recruiting to completed, as results have been reported in an iCo Therapeutics media release
    • 18 May 2010 The primary endpoint, ocular safety and tolerability, has been met, according to an iCo Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top